Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Non Operating Income (2016 - 2026)

Spyre Therapeutics' Other Non Operating Income history spans 11 years, with the latest figure at -$12.5 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 1427.75% year-over-year to -$12.5 million; the TTM value through Dec 2025 reached $29.5 million, up 242.22%, while the annual FY2025 figure was $29.5 million, 242.22% up from the prior year.
  • Other Non Operating Income reached -$12.5 million in Q4 2025 per SYRE's latest filing, down from $40.3 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $40.3 million in Q3 2025 to a low of -$21.4 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is -$526950.0, with a median of -$31500.0 recorded in 2021.
  • The largest YoY upside for Other Non Operating Income was 9658.33% in 2023 against a maximum downside of 66750.0% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at -$15000.0 in 2021, then crashed by 113.33% to -$32000.0 in 2022, then crashed by 66750.0% to -$21.4 million in 2023, then skyrocketed by 96.18% to -$818000.0 in 2024, then tumbled by 1427.75% to -$12.5 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Other Non Operating Income are -$12.5 million (Q4 2025), $40.3 million (Q3 2025), and -$656000.0 (Q2 2025).